MONOVISC and ORTHOVISC sales volumes and market share in US viscosupplementation market (estimated $500-600M annually)
FDA approval progress and commercial launch timelines for pipeline products in joint preservation and regenerative medicine
Medicare and private payer reimbursement policy changes for viscosupplementation procedures (CPT codes)
Strategic partnership announcements or M&A activity given small market cap and negative cash flow
moderate - Elective orthopedic procedures and viscosupplementation treatments show some correlation with consumer confidence and employment levels, as patients may defer non-urgent joint pain treatments during economic downturns. However, the aging demographic trend (65+ population growth) provides structural demand support. Commercial insurance coverage and out-of-pocket costs influence utilization rates, making the business somewhat sensitive to consumer financial health. Industrial production and employment levels indirectly affect workplace injury rates and subsequent orthopedic treatment demand.
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting small-cap healthcare stocks trading at premium valuations, and (2) increased financing costs if the company needs to raise capital given negative free cash flow. With debt/equity of only 0.17, current debt service impact is minimal. However, the company's ability to fund operations through equity markets becomes more challenging in higher-rate environments as investor appetite for cash-burning small caps diminishes.
Medicare reimbursement pressure on viscosupplementation procedures as CMS scrutinizes cost-effectiveness versus corticosteroid injections and physical therapy alternatives, with potential coverage restrictions
Competitive displacement from emerging cell-based therapies, platelet-rich plasma (PRP) treatments, and next-generation biologics that may offer superior efficacy for joint preservation
Regulatory pathway uncertainty for regenerative medicine products as FDA evolves guidance on combination products and tissue-engineered therapies
value/turnaround - The stock trades at 1.0x book value and 1.9x sales with negative profitability, attracting deep-value investors betting on operational turnaround, cost restructuring, or M&A takeout potential. The 32% EPS growth (from reduced losses) and recent 6-month return of 19.9% suggest some speculative interest in a recovery narrative. However, the -41.3% one-year return and negative margins deter growth investors. This profile appeals to small-cap value managers, special situations funds, and potential strategic acquirers in the orthopedic device space seeking bolt-on technology.
No analyst coverage available for this stock.
Trend
+54.1% vs SMA 50 · +43.1% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANIK News
Unable to load news
About
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ANIK◀ | $14.85 | +19.28% | $199M | — | -591.1% | -964.4% | 1500 |
| $68.56 | -3.59% | $13.3B | — | +12626.1% | -14525.8% | 1500 | |
| $513.72 | -0.71% | $11.8B | — | +43205.3% | -3008.0% | 1500 | |
| $87.60 | +0.60% | $11.5B | — | +3288.2% | -4239.0% | 1500 | |
| $183.72 | -1.59% | $10.7B | 29.2 | +1871.5% | 680.1% | 1500 | |
| $206.53 | -0.59% | $10.6B | — | +6554.5% | -2868.8% | 1500 | |
| $74.81 | +1.81% | $10.5B | 51.8 | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | +2.17% | — | 40.5 | +341824.3% | -3563.6% | 1500 |